
Curaleaf Holdings, Inc. (OTCMKTS:CURLF – Free Report) – Analysts at Atb Cap Markets cut their FY2025 earnings per share (EPS) estimates for Curaleaf in a research note issued on Thursday, November 6th. Atb Cap Markets analyst F. Gomes now forecasts that the company will earn ($0.32) per share for the year, down from their previous forecast of ($0.29). Atb Cap Markets currently has a “Hold” rating on the stock. The consensus estimate for Curaleaf’s current full-year earnings is ($0.25) per share. Atb Cap Markets also issued estimates for Curaleaf’s Q4 2025 earnings at ($0.08) EPS, FY2026 earnings at ($0.27) EPS, FY2027 earnings at ($0.21) EPS, FY2028 earnings at ($0.15) EPS and FY2029 earnings at ($0.09) EPS.
Curaleaf (OTCMKTS:CURLF – Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative return on equity of 15.57% and a negative net margin of 19.50%.
Get Our Latest Stock Analysis on Curaleaf
Curaleaf Trading Up 9.7%
OTCMKTS CURLF opened at $2.67 on Monday. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of -8.33 and a beta of 0.71. Curaleaf has a one year low of $0.68 and a one year high of $3.65. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.47 and a quick ratio of 0.71. The business’s fifty day moving average is $2.85 and its 200-day moving average is $1.86.
About Curaleaf
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Further Reading
- Five stocks we like better than Curaleaf
- Why Are These Companies Considered Blue Chips?
- 3 Big Earnings Misses: Is It Time to Buy the Dip?
- 3 Fintech Stocks With Good 2021 Prospects
- Is Robinhood’s 11% Post-Earnings Fall a Buy-the-Dip Opportunity?
- About the Markup Calculator
- AI Demand Is Coming—Is Microchip Technology Ready?
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.
